ArticlePLoS medicine2017
Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Article in PLoS medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT06473870 (Understanding Lung Cancer Related Risk Factors and Their Impact), which is not on this map. Cited by 155 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Understanding Lung Cancer Related Risk Factors and Their Impact
Who cites it
155 citing papers in PubMed, 11 syntheses or guidelines pooled it, 277 citations in OpenAlex.
- Use and impact of risk-based eligibility models in low-dose computed tomography lung cancer screening: a systematic review.Public health reviews · 2026Pooled it
- An umbrella review of systematic evidence on the Low Dose Computed Tomography (LDCT) for lung cancer screening.Future oncology (London, England) · 2025Pooled it
- Predictive performance of risk prediction models for lung cancer incidence in Western and Asian countries: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Pooled it
- [China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2023 Version)].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Guideline
- A systematic review of genetic ancestry as a risk factor for incidence of non-small cell lung cancer in the US.Frontiers in genetics · 2023Pooled it
- Association between metabolically healthy obesity and metastasis in lung cancer patients - a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification.PharmacoEconomics - open · 2022Pooled it
- Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.The Cochrane database of systematic reviews · 2022Pooled it
- Risk Prediction Model for Esophageal Cancer Among General Population: A Systematic Review.Frontiers in public health · 2021Pooled it
- Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Guideline
- Trial
- Immediate smoking cessation support versus usual care in smokers attending a targeted lung health check: the QuLIT trial.BMJ open respiratory research · 2022Trial
- Estimation of Cost for Endoscopic Screening for Esophageal Cancer in a High-Risk Population in Rural China: Results from a Population-Level Randomized Controlled Trial.PharmacoEconomics · 2019Trial
- Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.JAMA network open · 2019Trial
- 'Reduced' HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial.BMJ open respiratory research · 2019Trial
- Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Trial
- A Validated Clinical Risk Prediction Model for Lung Cancer in Smokers of All Ages and Exposure Types: A HUNT Study.EBioMedicine · 2018Trial
- Lung cancer risk prediction models and asbestos exposure: a validation study on the Western Australia Asbestos Review Program.Occupational and environmental medicine · 2026Article
- Clinical usefulness of polygenic risk scores in risk prediction models for lung cancer screening and lung nodule management.Translational oncology · 2026Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundSelection of candidates for lung cancer screening based on individual risk has been proposed as an alternative to criteria based on age and cumulative smoking exposure (pack-years). Nine previously established risk models were assessed for their ability to identify those most likely to develop or die from lung cancer. All models considered age and various aspects of smoking exposure (smoking status, smoking duration, cigarettes per day, pack-years smoked, time since smoking cessation) as risk predictors. In addition, some models considered factors such as gender, race, ethnicity, education, body mass index, chronic obstructive pulmonary disease, emphysema, personal history of cancer, personal history of pneumonia, and family history of lung cancer. METHODS AND
findingsRetrospective analyses were performed on 53,452 National Lung Screening Trial (NLST) participants (1,925 lung cancer cases and 884 lung cancer deaths) and 80,672 Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) ever-smoking participants (1,463 lung cancer cases and 915 lung cancer deaths). Six-year lung cancer incidence and mortality risk predictions were assessed for (1) calibration (graphically) by comparing the agreement between the predicted and the observed risks, (2) discrimination (area under the receiver operating characteristic curve [AUC]) between individuals with and without lung cancer (death), and (3) clinical usefulness (net benefit in decision curve analysis) by identifying risk thresholds at which applying risk-based eligibility would improve lung cancer screening efficacy. To further assess performance, risk model sensitivities and specificities in the PLCO were compared to those based on the NLST eligibility criteria. Calibration was satisfactory, but discrimination ranged widely (AUCs from 0.61 to 0.81). The models outperformed the NLST eligibility criteria over a substantial range of risk thresholds in decision curve analysis, with a higher sensitivity for all models and a slightly higher specificity for some models. The PLCOm2012, Bach, and Two-Stage Clonal Expansion incidence models had the best overall performance, with AUCs >0.68 in the NLST and >0.77 in the PLCO. These three models had the highest sensitivity and specificity for predicting 6-y lung cancer incidence in the PLCO chest radiography arm, with sensitivities >79.8% and specificities >62.3%. In contrast, the NLST eligibility criteria yielded a sensitivity of 71.4% and a specificity of 62.2%. Limitations of this study include the lack of identification of optimal risk thresholds, as this requires additional information on the long-term benefits (e.g., life-years gained and mortality reduction) and harms (e.g., overdiagnosis) of risk-based screening strategies using these models. In addition, information on some predictor variables included in the risk prediction models was not available.
conclusionsSelection of individuals for lung cancer screening using individual risk is superior to selection criteria based on age and pack-years alone. The benefits, harms, and feasibility of implementing lung cancer screening policies based on risk prediction models should be assessed and compared with those of current recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.